Results 81 to 90 of about 8,597,475 (170)

Impact of Baseline Central Retinal Thickness on Outcomes in the VIVID-DME and VISTA-DME Studies

Journal of Ophthalmology, 2018
Purpose. To report the impact of baseline central retinal thickness (CRT) on outcomes in patients with diabetic macular edema (DME) in VIVID-DME and VISTA-DME. Methods.
Edoardo Midena, Mark Gillies, Todd A. Katz, Carola Metzig, Chengxing Lu, Yuichiro Ogura   +5 more
doaj   +1 more source

Tolerability and safety of intravitreal aflibercept 8 mg in the Phase 3 PULSAR trial of patients with neovascular age-related macular degeneration

, 2023
Purpose : In PULSAR (NCT04423718), the primary endpoint of change from baseline in best-corrected visual acuity at Week 48 (non-inferiority margin at 4 letters) was met with intravitreal aflibercept 8 mg every 12 or 16 weeks (8q12 or 8q16) vs aflibercept
SCHMIDT-OTT, Ursula Maria, KOROBELNIK, Jean-Francois, SCHULZE, Andrea, ZHANG, Xin, LEAL, Sergio   +4 more
core   +1 more source

BCVA gains with aflibercept 8 mg maintained through Week 96 in PULSAR with extended treatment intervals in patients with nAMD

International audiencePurpose : To evaluate aflibercept 8 mg vs aflibercept 2 mg in patients with treatment-naïve neovascular age-related macular degeneration (nAMD). Methods : PULSAR (NCT04423718) is a double-masked, 96-week, Phase 3 trial.
Sivaprasad, S., Korobelnik, Jean-Francois   +1 more
core  

Intravitreal aflibercept 8 mg in patients from Japan with neovascular age-related macular degeneration: 48-week subgroup analysis of the PULSAR trial

PURPOSE: To evaluate the 1-year efficacy and safety of aflibercept 8 mg compared with aflibercept 2 mg in a pre-specified analysis of patients from Japan with neovascular age-related macular degeneration (nAMD) included in PULSAR.
Zhang, Xin, Berliner, Alyson J., Vitti, Robert, Reed, Kimberly, Bhore, Rafia, Yamashita, Takuto, Fujita, Ikuko, Cheng, Yenchieh, Sekiryu, Tetsuju, Zhao, Min, Leal, Sergio, Yasukawa, Tsutomu, Schmidt-Ott, Ursula, Honda, Shigeru, Chu, Karen W., Koizumi, Hideki, Iida, Tomohiro, Kishino, Genichiro, Schulze, Andrea   +18 more
core   +1 more source

Sterile endophthalmitis following same-day intravitreal aflibercept 8 mg injections: a single-center observational study

Background Aflibercept 8 mg was developed to extend treatment intervals in neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Although pivotal trials reported low rates of intraocular inflammation (IOI), post-marketing
Christos Papadimitriou, Daniel Meller, Fotios Papandreou, Menelaos Papadimitriou, Vasiliki Chioti   +4 more
core   +1 more source

Noninfectious Intraocular Inflammation After Intravitreal Aflibercept.

IMPORTANCE: Aflibercept, 8 mg, is an anti-vascular endothelial growth factor (VEGF) formulation for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).
Binder, Karoline E;Bleidißel, Nathalie;Charbel Issa, Peter;Maier, Mathias;Coulibaly, Leonard M
core   +1 more source

Comparison of the efficacy and safety of SCD411 and reference aflibercept in patients with neovascular age-related macular degeneration

Scientific Reports
To compare the efficacy and safety of the proposed aflibercept biosimilar SCD411 and reference aflibercept in patients with neovascular age-related macular degeneration, this randomized, double-masked, parallel-group, multicenter study was conducted in ...
Se Woong Kang, Jaehwan Choi, Veeral S. Sheth, Agnieszka Nowosielska, Marta Misiuk-Hojlo, András Papp, David M. Brown, Jae-Ho Lee, Yoreh Barak   +8 more
doaj   +1 more source

Resolution of subretinal fluid in intractable central serous chorioretinopathy with high-dose intravitreal aflibercept

American Journal of Ophthalmology Case Reports
Purpose: To report an unusual case of a patient with intractable central serous chorioretinopathy with a dramatic treatment response to high-dose intravitreal aflibercept. Methods: Retrospective case report.
Jonathan B. Lin, Loh-Shan B. Leung
doaj   +1 more source

Randomised, double-masked trial to compare the efficacy, safety and immunogenicity of the biosimilar aflibercept FYB203 with reference aflibercept in patients with neovascular age-related macular degeneration

BMJ Open Ophthalmology
Objective Biosimilars are helping to reduce the cost burden of treatment and widen patient access to therapies. This multicentre trial compared the efficacy, safety and immunogenicity of the biosimilar aflibercept FYB203 with reference aflibercept in ...
András Papp, Sigrid Balser, Björn Capsius, Rahul Hole, Nicole Preissinger, Alexis Rozenknop, Theodor Tiko   +6 more
doaj   +1 more source

Cost-effectiveness of ranibizumab versus aflibercept in the treatment of visual impairment due to diabetic macular edema: a UK healthcare perspective

, 2015
Stephane A Régnier,1 William Malcolm,2 Jennifer Haig,3 Weiguang Xue41Novartis Pharma AG, Basel, Switzerland; 2Novartis Pharmaceuticals UK Ltd, Frimley Business Park, UK; 3Optum, Burlington, ON, Canada; 4Optum, Uxbridge, UKBackground: Ranibizumab ...
Xue W, Haig J, Régnier SA, Malcolm W   +3 more
core